MeiraGTx to Participate in Upcoming Investor Conferences

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

MeiraGTx Holdings plc (NASDAQ: MGTX) announced its participation in upcoming investor conferences. Alexandria Forbes, Ph.D., President, and CEO will present at Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, BofA Securities Healthcare Conference 2024, and Goldman Sachs 45th Annual Global Healthcare Conference. Live webcasts will be available on the Investors page of the Company's website.

LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences:

• Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, Virtual
  

Corporate presentation: Monday, April 29, 2024, at 11:00 a.m. ET

•  BofA Securities Healthcare Conference 2024, Las Vegas
  

Corporate presentation: Wednesday, May 15, 2024, at 10:40 a.m. PT

•  Goldman Sachs 45th Annual Global Healthcare Conference, Miami
  

Corporate presentation: Wednesday, June 12, 2024, at 2:40 p.m. ET

A live webcast of the corporate presentations will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. Replays will be available for approximately 30 days following the presentation dates.

About MeiraGTx
MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage gene therapy company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.

For more information, please visit www.meiragtx.com.

FAQ

When will MeiraGTx participate in the Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit?

MeiraGTx will participate in the Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024, at 11:00 a.m. ET.

What is the date and time of MeiraGTx's presentation at the BofA Securities Healthcare Conference 2024?

MeiraGTx will present at the BofA Securities Healthcare Conference 2024 on Wednesday, May 15, 2024, at 10:40 a.m. PT.

Where will MeiraGTx participate in the Goldman Sachs 45th Annual Global Healthcare Conference?

MeiraGTx will participate in the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Wednesday, June 12, 2024, at 2:40 p.m. ET.

Where can investors watch the live webcast of MeiraGTx's corporate presentations?

Investors can watch the live webcast of MeiraGTx's corporate presentations on the Investors page of the Company's website at www.investors.meiragtx.com.

For how long will replays of the corporate presentations be available?

Replays of the corporate presentations will be available for approximately 30 days following the presentation dates.